论文部分内容阅读
动物实验证实HB_s Ag iRNA 具有过继对HB_s Ag的特异性细胞免疫和体液免疫的作用。应用HB_s Ag iRNA治疗后可以使原来HP_s Ag刺激白细胞粘附抑制试验(LAI)阴性慢性乙型肝炎(简称慢乙肝)患者的淋巴细胞变为LAI阳性,并可促进抗-HB_s的生成。国内已有报道,认为对慢乙肝有一定治疗效果,对降低血清HB_s Ag滴度、促进HB_s Ag阴转有一定作用。我们于1982年9月至1983年6月应用HB_s Ag iRNA穴位注射对50例HB_s Ag阳性的慢性活动性肝炎(简称慢活肝)、慢性迁延性肝炎(简称慢迁脚下肝)和无症状HB_sAg携带者进行了治疗观察,报道于下。
Animal experiments confirmed that HB_s Ag iRNA has the effect of inheriting specific cellular immunity and humoral immunity to HB_s Ag. After treatment with HBsAg iRNA, the lymphocytes of patients with original HP_s Ag-stimulated leukocyte adhesion inhibition test (LAI) -negative chronic hepatitis B (referred to as chronic hepatitis B) become LAI-positive and promote the generation of anti-HBs. It has been reported in China that there is a certain therapeutic effect on chronic hepatitis B, which can reduce HBsAg titer in serum and promote HBsAg negative conversion. We used HB_sAg iRNA acupoint injection from September 1982 to June 1983 in 50 cases of HB_s Ag positive chronic active hepatitis (referred to as slow living liver), chronic persistent hepatitis (referred to as slow migration of the foot of the liver) and asymptomatic HB_sAg Carriers were treated for observation, reported below.